Robbins K Thomas, Doweck Ilana, Samant Sandeep, Vieira Francisco, Kumar Parvesh
University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Laryngoscope. 2004 Mar;114(3):411-7. doi: 10.1097/00005537-200403000-00004.
To determine the relative risk of prognostic factors for local disease control following RADPLAT.
Prospective study, academic medical center.
Analyses of nine categories of risk factors among 240 patients with Stage II-IV carcinoma consecutively treated with RADPLAT (cisplatin 150 mg/m IA and sodium thiosulfate 9 g/m IV, weekly x4; radiotherapy 2 Gy/fraction/d, 5x weekly, 68-74 Gy over 6 to 7 weeks). Median follow-up: 58 months (range, 12-96 mo).
The percentage of patients who had local disease control was 87.5%. Univariant analysis showed T classification (P =.01), laterality of neck disease (P =.026), number of neck levels involved (P =.008), total dose of radiation greater versus less than 60 Gy (P =.027), and presence of pathologically positive lymph nodes following chemoradiation (P =.01) to be significant. Logistic regression analysis showed total dose of radiation (P =.03) and the presence of pathologically positive lymph nodes following chemoradiation (P =.05) to be significant. For Kaplan-Meier estimates of local disease control at 5 years, T classification (P =.038), number of levels with nodal disease (P =.006), and total dose of radiation therapy (P =.0001) were significant. The log-rank test identified as significant the total dose of radiation therapy (P <.0001), the presence of pathologically positive lymph nodes following chemoradiation (P =.005), and the number of neck levels with positive nodes (P =.006). The Cox regression model showed significance for the total dose of radiation (P =.001), the presence of pathologically positive lymph nodes following chemoradiation (P =.007), and the T classification (P =.029).
Risk factors significantly associated with local disease control after RADPLAT appears to differ from more traditional therapy and is suggestive of a paradigm shift.
确定接受放疗联合顺铂治疗(RADPLAT)后局部疾病控制的预后因素的相对风险。
前瞻性研究,学术医疗中心。
对240例II-IV期癌症患者的九类风险因素进行分析,这些患者连续接受RADPLAT治疗(顺铂150mg/m² 动脉内注射,硫代硫酸钠9g/m² 静脉注射,每周一次,共4次;放疗2Gy/分次/天,每周5次,6至7周内给予68-74Gy)。中位随访时间:58个月(范围12-96个月)。
局部疾病得到控制的患者百分比为87.5%。单因素分析显示T分类(P = 0.01)、颈部疾病的侧别(P = 0.026)、受累颈部淋巴结水平数(P = 0.008)、放疗总剂量大于或小于60Gy(P = 0.027)以及放化疗后病理阳性淋巴结的存在(P = 0.01)具有显著性。逻辑回归分析显示放疗总剂量(P = 0.03)和放化疗后病理阳性淋巴结的存在(P = 0.05)具有显著性。对于5年局部疾病控制的Kaplan-Meier估计,T分类(P = 0.038)、有淋巴结疾病的水平数(P = 0.006)和放疗总剂量(P = 0.0001)具有显著性。对数秩检验确定放疗总剂量(P < 0.0001)、放化疗后病理阳性淋巴结的存在(P = 0.005)和有阳性淋巴结的颈部水平数(P = 0.006)具有显著性。Cox回归模型显示放疗总剂量(P = 0.001)、放化疗后病理阳性淋巴结的存在(P = 0.007)和T分类(P = 0.029)具有显著性。
与RADPLAT治疗后局部疾病控制显著相关的风险因素似乎与更传统的治疗方法不同,提示了一种模式转变。